OPT News and Press, Opthea Limited From 04/06/21

MELBOURNE, Australia, April 06, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT) advises that Mr Michael Tonroe has resigned as Company Secretary and Chief Financial Officer (CFO) of the Company, with effect 24 June 2021. Opthea has initiated a search for a permanent replacemen...

Opthea (OPT) jumps 6% premarket on receipt of an initial Pediatric Study Plan (iPSP) waiver from the FDA for its lead product candidate OPT-302, currently in Phase 3 development for the treatment of neovascular (wet) age-related macular degeneration.The receipt of the agreed iPSP wa...

MELBOURNE, Australia, March 31, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progressive retinal diseases, today announces that it has received an initial Pediatric Study Pl...

MELBOURNE, Australia, March 10, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT, Nasdaq: OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progressive retinal diseases, today announced that Dr Megan Baldwin, CEO of Opthea, will virtua...

Following consultations with US FDA and EU EMA, two pivotal Phase 3 clinical trial designs are finalized to assess 2 mg OPT-302 administered 4-weekly or 8-weekly in combination with Lucentis® (ShORe study) and Eylea® (COAST study) standard of care Internation...

MELBOURNE, Australia, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT, Nasdaq: OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progressive retinal diseases, today announced that Dr Megan Baldwin, CEO of Opthea, will virtual...